Mucosal vaccination against bacterial respiratory infections (Q37290114)

19 August 2017

1 reference

title

Mucosal vaccination against bacterial respiratory infections (English)

1 reference

19 August 2017

Ulrich Baumann

1

1 reference

19 August 2017

1 October 2008

1 reference

Expert Review of Vaccines

19 August 2017

1 reference

19 August 2017

7

1 reference

19 August 2017

8

1 reference

19 August 2017

1257-1276

1 reference

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Novel approaches to fight Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

The neglected intrinsic resistome of bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Development of new tuberculosis vaccines: a global perspective on regulatory issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Vaccine approaches to prevent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Complement deficiency and disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Role of secretory antibodies in the defence against infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Immune response versus mucosal tolerance to mucosally administered antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal vaccines for protection against respiratory and systemic bacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Noninvasive delivery technologies: respiratory delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Live attenuated versus inactivated influenza vaccine in infants and young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Sublingual vaccination with influenza virus protects mice against lethal viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Bordetella pertussis from functional genomics to intranasal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Bacterial ghosts as adjuvant particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Rational design of Salmonella recombinant vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Improving vaccines by incorporating immunological coadjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Mucosal immunisation of murine neonates using whole cell and acellular Pertussis vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Recent findings in immunology give tuberculosis vaccines a new boost

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Should a new tuberculosis vaccine be administered intranasally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Local application of CpG oligodeoxynucleotide enhances nontypeable Haemophilus influenzae-specific mucosal IgA responses in the middle ear

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

Nasal boost with adjuvanted heat-killed BCG or arabinomannan–protein conjugate improves primary BCG-induced protection in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1257

10.1586/14760584.7.8.1257

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18844598